Biofarm S.A. Stock

BIO

ROBIOFACNOR9

Pharmaceuticals

End-of-day quote Bucharest S.E. 2026-08-24			5-day change	1st Jan Change
1.370 ^RON	+0.74%		-.--%	+69.14%

08-14	Biofarm S.A. Reports Earnings Results for the Half Year Ended June 30, 2026	CI
06-23	Polpharma SA Pharmaceutical Works completed the acquisition of Biofarm S.A. from Longshield Investment Group SA, Lion Capital S.A. and other shareholders.	CI

Biofarm SA is a Romania-based company engaged in the pharmaceutical sector. The Company focuses on the production and marketing of pharmaceutical preparations. The Company is active in the manufacture and wholesale of over the counter drugs, prescription medications and dietary supplements. The Companyâ€™s product portfolio includes pharmaceutical preparations for digestive system, musculoskeletal system, immune stimulation, respiratory system, cold and flu symptoms and venous circulation improvement, as well as multivitamins, antioxidants, antiseptics, disinfectants and cosmetics, among others. Additionally, the Company offers services, such as consultancy on Romanian pharmaceutical market, manufacturing of non-sterile products, the investment in research, promotion and packaging. The main shareholder of the Company is Societatea de Investitii Financiare Muntenia SA.

Employees

374

Sector

Pharmaceuticals

Calendar

11-12

More about the company

The best tools reserved for subscribers to boost the performance of your investments!

Market Cap	1.35B 291M 256M 242M 219M 412M 27.91B 414M 2.9B 1.12B 14.24B 1.09B 1.07B 45.77B	P/E 2024	10.4x	P/E 2025	8.79x
Enterprise Value	1.18B 254M 224M 212M 192M 360M 24.42B 362M 2.53B 978M 12.46B 955M 934M 40.04B	EV / Sales 2024	2.03x	EV / Sales 2025	1.97x
Free-Float	7.26%	Yield 2024	4.34%	Yield 2025	5.19%

Markets		Quality
Bucharest S.E.	BIO	End-of-day quote
Deutsche Boerse AG	H3D	Delayed

08-14	Biofarm S.A. Reports Earnings Results for the Half Year Ended June 30, 2026	CI
06-23	Polpharma SA Pharmaceutical Works completed the acquisition of Biofarm S.A. from Longshield Investment Group SA, Lion Capital S.A. and other shareholders.	CI
05-05	Biofarm S.A. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-05	Polpharma SA Pharmaceutical Works proposed to acquire Biofarm S.A. from Longshield Investment Group SA, Lion Capital S.A. and other shareholders for RON 1.4 billion.	CI
03-23	Biofarm S.A. announces Annual dividend, payable on May 29, 2026	CI
02-26	Biofarm S.A. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
11-14	Biofarm S.A. Reports Earnings Results for the Nine Months Ended September 30, 2025	CI
25-08-13	Biofarm S.A. Reports Earnings Results for the Half Year Ended June 30, 2025	CI
25-05-13	Biofarm S.A. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
25-03-20	Biofarm S.A. announces Annual dividend, payable on September 05, 2025	CI
25-02-27	Biofarm S.A. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
24-11-13	Biofarm S.A. Reports Earnings Results for the Nine Months Ended September 30, 2024	CI
24-08-21	Biofarm S.A. Reports Earnings Results for the Half Year Ended June 30, 2024	CI

01-12	Biofarm S A : 2026-01-12 Current Report Evaluation of strategic options regarding the development of the Company	PU
11-28	Biofarm S A : 2025-11-28 Current Report	PU
11-14	Biofarm S A : 2025-09-30 Administrator Report - IFRS Financial Statements	PU
11-14	Biofarm S A : 2025-11-14 Communique	PU
11-12	Biofarm S A : 2025-11-12 Current Report	PU

1 day	+0.74%
3 months	-8.36%
6 months	+6.61%
Current year	+69.14%

Biofarm S.A. Stock

Stocks

BIO

ROBIOFACNOR9

Pharmaceuticals

Valuation: Biofarm S.A.

Chart: Biofarm S.A.

Latest news: Biofarm S.A.

Press Releases: Biofarm S.A.

Quotes and Performance

Price Extremes

Managers and Directors: Biofarm S.A.

Generic Pharmaceuticals

Financials

Company Profile

Current year	0.81	1.5
1 year	0.78	1.5
3 years	0.62	1.5
5 years	0.53	1.5
10 years	0.26	1.5

Manager	Title	Age	Since
Catalin Vicol CEO	Chief Executive Officer	51	2018-11-14
Mihai Zoescu DFI	Director of Finance/CFO	46	2021-01-17
Mirel Florica COO	Chief Operating Officer	-	2023-08-31

Director	Title	Age	Since
Andrei Hrebenciuc CHM	Chairman	42	2018-12-30
Bogdan-Alexandru Dragoi BRD	Director/Board Member	46	2015-12-09
Catalin Vicol BRD	Director/Board Member	51	2018-11-14

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
BIOFARM S.A.	+0.74%	-.--%	+66.67%	+77.92%	292M
SUN PHARMACEUTICAL INDUSTRIES LTD.	-0.77%	+0.04%	+15.84%	+61.24%	46.37B
OTSUKA HOLDINGS CO., LTD.	+1.76%	+2.22%	+45.61%	+111.49%	37.26B
ZYDUS LIFESCIENCES LIMITED	+0.92%	+4.74%	+24.62%	+100.78%	12.53B
CIPLA LIMITED	-1.14%	-0.77%	-7.72%	+17.21%	11.8B
KRKA, D. D.	+0.19%	+0.19%	+17.87%	+140.09%	8.97B
ONO PHARMACEUTICAL CO., LTD.	-0.82%	-2.39%	+38.85%	-18.35%	7.29B
GEDEON RICHTER	-0.64%	-3.35%	+26.92%	+37.17%	7.09B
GLENMARK PHARMACEUTICALS LIMITED	-2.28%	-4.97%	+17.95%	+199.55%	7.01B
SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD.	-1.19%	-1.78%	-50.77%	+1.98%	4.99B
Average	-0.31%	-0.02%	+19.58%	+72.91%	14.36B
Weighted average by Cap.	+0.01%	+0.42%	+22.13%	+78.53%

	2024	2025
Net sales	287M 61.77M 54.33M 51.38M 46.6M 87.51M 5.93B 88.02M 615M 238M 3.03B 232M 227M 9.72B	319M 68.79M 60.5M 57.21M 51.89M 97.45M 6.6B 98.02M 685M 265M 3.37B 258M 253M 10.83B
Net income	74.4M 16.03M 14.1M 13.33M 12.09M 22.7M 1.54B 22.84M 160M 61.63M 785M 60.17M 58.87M 2.52B	101M 21.68M 19.07M 18.03M 16.35M 30.71M 2.08B 30.89M 216M 83.37M 1.06B 81.39M 79.63M 3.41B
Net Debt	-123M -26.46M -23.27M -22.01M -19.96M -37.48M -2.54B -37.7M -263M -102M -1.3B -99.34M -97.19M -4.16B	-169M -36.43M -32.04M -30.3M -27.48M -51.61M -3.5B -51.91M -363M -140M -1.78B -137M -134M -5.73B